Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06356311 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

A Phase 3 study of GastroEsophageal Cancer, sponsored by Merck Sharp & Dohme.

Active
Registry status
Phase 3
Development phase
450
Enrollment target
20
Study locations

NCT06356311 is a Phase 3 study of GastroEsophageal Cancer that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 450 participants, roughly in line with the 477-participant average among 23 other GastroEsophageal Cancer trials with a reported enrollment target. The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06356311, a Phase 3 study of GastroEsophageal Cancer, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
450 participants
Enrollment target
20
Study locations

Study Summary

This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Overall Survival (OS).

Conditions Studied

GastroEsophageal Cancer

Interventions

  • BIOLOGICAL Sacituzumab tirumotecan
  • DRUG Docetaxel
  • DRUG Paclitaxel
  • DRUG Irinotecan
  • DRUG Trifluridine-Tipiracil

Study Locations (20)

Kentucky

  • University of Kentucky Chandler Medical Center-Medical Oncology ( Site 0124) - Lexington
  • The University of Louisville, James Graham Brown Cancer Center-James Graham Brown Cancer Center ( Site 0113) - Louisville
  • Norton Audubon Hospital-Norton Cancer Institute - Audubon ( Site 0105) - Louisville

Bruxelles-Capitale, Region de

  • Institut Jules Bordet-GastroIntestinal Medical Oncology ( Site 1003) - Anderlecht
  • Cliniques universitaires Saint-Luc-Medical Oncology ( Site 1001) - Brussels

Arizona

  • Banner MD Anderson Cancer Center ( Site 0119) - Gilbert

California

  • UCLA Hematology/Oncology - Santa Monica ( Site 0140) - Los Angeles

Florida

  • AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0129) - Orlando

Georgia

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0108) - Marietta

Illinois

  • University of Chicago Medical Center ( Site 0120) - Chicago

Michigan

  • Henry Ford Hospital ( Site 0107) - Detroit

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 2024-05-03
Est. Completion 2027-05-06
Phase Phase 3

Sponsor

Merck Sharp & Dohme

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06356311

The ClinicalTrials.gov registry entry for NCT06356311 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 477-participant average among 23 other GastroEsophageal Cancer trials with a reported enrollment target. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with GastroEsophageal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Sacituzumab tirumotecan is the first listed.

NCT06356311 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Kentucky, Bruxelles-Capitale, Region de, Arizona.

Frequently Asked Questions

What is clinical trial NCT06356311 about?

NCT06356311 is a clinical study titled "A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)". This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Over...

What is the current status of trial NCT06356311?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2024-05-03. Estimated completion is 2027-05-06.

What conditions does trial NCT06356311 study?

This clinical trial studies the following conditions: GastroEsophageal Cancer.

What interventions are being tested in trial NCT06356311?

The interventions under investigation include: Sacituzumab tirumotecan (BIOLOGICAL), Docetaxel (DRUG), Paclitaxel (DRUG), Irinotecan (DRUG), Trifluridine-Tipiracil (DRUG).

Who is sponsoring clinical trial NCT06356311?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06356311 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for GastroEsophageal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

GastroEsophageal Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.